PDCD1 and neoplasm: Some molecular biomarkers, to name a few-microsatellite instability (MSI) [4], tumor mutational burden (TMB) [5], and programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) [6], have grown into indispensable predictors of immunotherapy efficacy.